



American
Urological
Association

Disclosure of Relevant Financial Relationships

*Research Education, Conference and
Communication Committee*

All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible companies during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The AUA must determine if the individual's relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments. All relevant financial relationships listed below have been mitigated.

<u>Name</u>	<u>Company Name</u>	<u>Relationship Type</u>	<u>End Date</u>
Kachroo, Naveen	Boston Scientific	Consultant or Advisor	Current
Belkoff, Laurence H.	Marius Pharmaceutical	Consultant or Advisor	Current
	Johnson & Johnson	Consultant or Advisor	Current
	Dendreon	Consultant or Advisor	Current
Khavari, Rose	Neilson Foundation	Scientific Study or Trial	Current
Kim, Simon	Status: Nothing to disclose		
Lai, Henry Henry	Medtronic	Scientific Study or Trial	Current
	Neuspera	Consultant or Advisor	01/31/2024
Molina, Wilson R.	Boston Scientific	Consultant or Advisor	Current
	Olympus	Consultant or Advisor	Current
	Fortec	Consultant or Advisor	12/31/2023
	IPG	Consultant or Advisor	Current
	Johnson & Johnson	Consultant or Advisor	Current
	STORZ	Consultant or Advisor	Current
Penniston, Kristina L.	Springer Publishing	Health Publishing	12/31/2023
Popovics, Petra	Status: Nothing to disclose		
Reynolds, William Stuart	Status: Nothing to disclose		
Salami, Simpa Samuel	Bayer Pharma	Scientific Study or Trial	Current
Singla, Nirmish	Status: Nothing to disclose		
Stern, Joshua	Status: Nothing to disclose		
Yates III, Clayton	Riptide Biosciences	Stock Option	Current
	QED Therapeutics	Consultant or Advisor	10/01/2023
	PreludeDX	Consultant or Advisor	Current
	Kaiser Permeate	Consultant or Advisor	Current